Impact Biomedical Inc.IBO

Impact BioMedical Inc. filed its 10-Q for the quarter ending 31 March 2026 on 12 May, revealing revenue from contracts with customers of $7,000, an operating loss of $2.3 million, and cash on hand of $20,000. The filing is the most recent financial window into a company whose 10-K, filed 11 March 2026, describes a focus on the discovery, development, and commercialisation of products addressing unmet needs in human health.

The company operates as a biomedical research and commercialisation business with a distribution agreement, dated 9 December 2020, through BioMed Technologies Asia Pacific Holdings Limited. That agreement requires commercial general liability and products liability insurance with limits of no less than $1 million per occurrence and $2 million in aggregate. The 10-K notes the company could lose emerging growth company status sooner if revenues exceed $1.235 billion or if it issues more than $1 billion in non-convertible debt over a three-year period, thresholds that look distant given current revenue levels.

The 10-Q for the period ending 31 March 2026 reports the following filed figures: revenue of $7,000, net loss attributable to parent of $2.3 million, operating loss of $2.3 million, diluted EPS of negative $0.02, cash and cash equivalents of $20,000, net cash used in operating activities of $464,000, R&D expense of $46,000, inventory net of $63,000, total assets of $17.1 million, liabilities of $2.4 million, and stockholders' equity attributable to parent of $11.5 million. The 10-K for the period ending 31 December 2025 reported a decrease in inventories of $7,000.

The SEC EDGAR filing index for CIK 1834105 shows a busy recent filing schedule: the 10-Q on 12 May 2026, a Form 144 on 29 April 2026, two S-8 POS filings on 22 April and 6 April 2026, and two Form 4 ownership filings on 30 March and 25 March 2026. The companyfacts and submissions JSON feeds are available through SEC EDGAR for further structured data. The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available.

What changed this quarter is primarily the cash position: $20,000 in cash against $464,000 of negative operating cash flow means the company is burning through its liquid reserves at a pace that raises going-concern questions the evidence rail does not explicitly answer. The $11.5 million in stockholders' equity provides a buffer on paper, but the composition of those assets and the path to revenue generation remain the central tension. The S-8 POS filings and Form 144 suggest equity-related activity, which is consistent with a company that needs capital and has limited operating cash to fund its burn.

What remains unproven from the supplied evidence is the specific product pipeline, any pending regulatory approvals, customer concentration, and the current status of the BioMed Technologies Asia Pacific distribution relationship beyond the 2020 agreement. The 10-K language is general, referring to discovery and commercialisation without naming specific products, clinical trial stages, or commercialised goods. The inventory figure of $63,000 suggests some physical product exists, but the evidence does not specify what it is or whether it is generating the $7,000 in quarterly revenue.

What would deepen this file is a subsequent filing disclosing cash raised through equity issuance after the quarter-end, a product-specific announcement or regulatory update, and any amendment or update to the 2020 distribution agreement that clarifies whether the Asia Pacific channel is active. Until then, the filed numbers speak clearly: a company with a biomedical mission, a distribution partner, minimal revenue, minimal cash, and a filing cadence that suggests the capital structure is doing more work than the operating business.